Emotion potentiated startle in fragile X syndrome

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment

Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by the full mutation as well as highly localized methylation of the fragile X mental retardation 1 (FMR1) gene on the long arm of the X chromosome. Children with FXS are commonly co-diagnosed with Autism Spectrum Disorder, attention and learning problems, anxiety, aggressive behavior and sleep disorder, and early interventions have improved many behavior symptoms associated with FXS. In this review, we performed a literature search of original and review articles data of clinical trials and book chapters using MEDLINE (1990-2021) and ClinicalTrials.gov. While we have reviewed the biological importance of the fragile X mental retardation protein (FMRP), the FXS phenotype, and current diagnosis techniques, the emphasis of this review is on clinical interventions. Early non-pharmacological interventions in combination with pharmacotherapy and targeted treatments aiming to reverse dysregulated brain pathways are the mainstream of treatment in FXS. Overall, early diagnosis and interventions are fundamental to achieve optimal clinical outcomes in FXS.

Correction of amygdalar dysfunction in a rat model of fragile X syndrome

Fragile X syndrome (FXS), a commonly inherited form of autism and intellectual disability, is associated with emotional symptoms that implicate dysfunction of the amygdala. However, current understanding of the pathogenesis of the disease is based primarily on studies in the hippocampus and neocortex, where FXS defects have been corrected by inhibiting group I metabotropic glutamate receptors (mGluRs). Here, we observe that activation, rather than inhibition, of mGluRs in the basolateral amygdala reverses impairments in a rat model of FXS. FXS rats exhibit deficient recall of auditory conditioned fear, which is accompanied by a range of in vitro and in vivo deficits in synaptic transmission and plasticity. We find presynaptic mGluR5 in the amygdala, activation of which reverses deficient synaptic transmission and plasticity, thereby restoring normal fear learning in FXS rats. This highlights the importance of modifying the prevailing mGluR-based framework for therapeutic strategies to include circuit-specific differences in FXS pathophysiology.

STARTLE RESPONSE ANALYSIS OF FOOD-IMAGE PROCESSING IN PRADER-WILLI SYNDROME

BACKGROUND

Prader-Willi syndrome (PWS) is a complex genetic neurodevelopmental disorder with endocrine disturbances, hyperphagia and often life-threatening obesity as key features. We investigated emotional-processing of food and eating behavior in PWS using startle response-modulation. Startle eyeblink response is an involuntary reflex activated by the autonomic nervous system in response to sudden or disturbing auditory/visual stimuli which may be modulated by the emotional valence of concurrently viewed visual stimuli.

METHODOLOGY

Differences in affective modulation of startle reflex were recorded in 13 individuals with PWS versus 8 healthy controls when viewing standard neutral, negative, positive and food-derived images. Electromyogram (EMG) of the orbicularis oculi muscle was measured in response to binaural white noise before and after consumption of a standard 500 Kcal meal. Participants reported their perceived emotional valence for each image, pre- and post-meal, using a 1-10 Likert rating scale.

RESULTS

Subjective ratings of food images and urge to eat were significantly higher in PWS than controls and did not significantly decline post-meal. Acoustic startle responding was detected in PWS but was significantly lower than control participants under all conditions. Startle responses to food images in PWS were attenuated relative to other picture types with potentially abnormal emotional modulation of responses to non-food images which contrasted self-reported picture ratings. A stable positive emotional valence to food images was observed pre- and post-feeding with a sustained urge to consume food in PWS.

CONCLUSIONS

Emotional processing measured using startle modulation in response to non-food images was abnormal in PWS which may reflect unique physiological attributes such as hypotonia and abnormal skin conductivity due to increased fat mass. Alternatively, disruption of autonomic or sympathetic nervous system functioning reported in PWS may impact on hunger and/or food drive states. Our findings parallel attentional/processing attributes of affective stimuli reported in autism spectrum disorder and support the feasibility of eyeblink startle modulation to assess food motivation in PWS and provide preliminary data to optimize methodological parameters.

Clinical and molecular implications of mosaicism in FMR1 full mutations

Expansions of more than 200 CGG repeats (full mutation) in the FMR1 gene give rise to fragile X syndrome (FXS) through a process that generally involves hypermethylation of the FMR1 promoter region and gene silencing, resulting in absence of expression of the encoded protein, FMRP. However, mosaicism with alleles differing in size and extent of methylation often exist within or between tissues of individuals with FXS. In the current work, CGG-repeat lengths and methylation status were assessed for eighteen individuals with FXS, including 13 mosaics, for which peripheral blood cells (PBMCs) and primary fibroblast cells were available. Our results show that for both PBMCs and fibroblasts, FMR1 mRNA and FMRP expression are directly correlated with the percent of methylation of the FMR1 allele. In addition, Full Scale IQ scores were inversely correlated with the percent methylation and positively correlated with higher FMRP expression. These latter results point toward a positive impact on cognition for full mutation mosaics with lower methylation compared to individuals with fully methylated, full mutation alleles. However, we did not observe a significant reduction in the number of seizures, nor in the severity of hyperactivity or autism spectrum disorder, among individuals with mosaic genotypes in the presentation of FXS. These observations suggest that low, but non-zero expression of FMRP may be sufficient to positively impact cognitive function in individuals with FXS, with methylation mosaicism (lowered methylation fraction) contributing to a more positive clinical outcome.